I-New Delhi: Ukuphendula isiphakamiso se-Fresenius Medical Care, i-Specialty Expert Committee (SEC) ye-Central Drugs Standard Control Organization (CDSCO) iphakamise bona inkampani ithumele isizathu sokuvunywa kanye nedatha yokuhlolwa kwezokwelapha yesigaba III se-calcium chloride dihydrate kanye nedatha yokuhlolisisa ngemva kokuphawula okuvela emazweni avunyelwe ukucatshangelwa okunye.
Inkampani ngaphambilini ifake isibawo sokwenza nokuthengisa isisombululo se-calcium chloride dihydrate ngesilinganiso esiyi-100 mmol/L, esisetjenziselwa “ukwelapha ukufaka esikhundleni se-calcium ekwelapheni okuragela phambili kokubuyiselwa kwezinso (CRRT), i-dialysis eragela phambili (i-CLED) kanye ne-therapeutic plasma exchange (TPE) nge-citrate umkhiqizo. ilungele abantu abadala nabantwana” begodu yatjho iinzathu zokungafakwa esigabeni se-III nesigaba se-4 seemhloliso zokwelapha.
Ikomidi litjheje bona umkhiqizo lo sele uvunyelwe emazweni we-Europe afana ne-Portugal, i-United Kingdom, i-Brazil, i-Switzerland, i-France ne-Denmark.
Ikhompawundi ye-calcium chloride dihydrate yi-CaCl2 2H2O, okuyi-calcium chloride equkethe amamolekhuli amabili wamanzi ngeyunithi ngayinye ye-calcium chloride. Yinto emhlophe enekristalu, encibilika lula emanzini begodu ine-hygroscopic, okutjho bona ikghona ukudosa umswakama ovela emoyeni.
I-calcium chloride dihydrate yikhompawundi engasetjenziswa njengesistimu yokuncibilikisa i-chitin lokha nayincibilikisa ku-methanol. Idlala indima eqakathekileko ekuphuleni isakhiwo sekristalu se-chitin begodu ineendlela ezinengi zokusetjenziswa emkhakheni wekhemistri.
Emhlanganweni we-SEC Nephrology owabanjwa mhlazi-20 kuMrhayili 2025, iphaneli ibuyekeze isiphakamiso sokuvuma ukukhiqizwa nokumaketha isisombululo se-100 mmol/L se-calcium chloride dihydrate infusion ukuze sisetjenziselwe “ekwelapheni okubuyisela i-calcium ekwelapheni okuragela phambili kokubuyiselwa kwezinso (CRRT), okuragela phambili nokusebenza okuphasi (i-DDDS) kanye nokwelapha ukutjhugululwa kwe-plasma (TPE) nge-citrate anticoagulation. Umkhiqizo utjengiswa ebantwini abadala nabantwana” begodu wanikela ngesizathu sokukhululwa ekuhlolweni kwezokwelapha kwesigaba III ne-IV.
Ngemva kokukhulumisana okunabileko, ikomidi iphakamise bona isisekelo sokuvunywa, kanye nedatha yesigaba se-III sokulinga kwezokwelapha kanye nedatha yokugada ngemva kokuthengisa evela emazweni avume umuthi, ithunyelwe ekomidini ukuze iqalwe ngokuragela phambili.
Funda godu: Isiqhema se-CDSCO sivuma ukulebula okuvuselelweko kwe-Myozyme ye-Sanofi, sibawa ukubuyekezwa komthetho
U-Dr. Divya Kolin mfundi we-PharmD onolwazi olubanzi lwezokwelapha nezesibhedlela kanye namakghono amahle khulu wokuhlola nokwelapha. Usebenze njengosokhemisi we-oncology emnyangweni we-oncology e-Mysore Medical College and Research Institute. Njenganje uragela phambili nomsebenzi wakhe wokurhubhulula kwezokwelapha nokuphathwa kwedatha yezokwelapha. Usebenza ne-Medical Dialogue kusukela ngoTjhirhweni 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Irhubhululo le-ABYSS lithole bona ukumisa ama-beta-blockers ngemva kokuhlaselwa yi-myocardial kuphumela ekukhuphukeni kwegandeleleko leengazi, ukubetha kwehliziyo, kanye nezehlakalo ezimbi zenhliziyo: ...